How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,918 results for

macrolides

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Long-term macrolide treatment for the prevention of acute exacerbations in COPD: a systematic review and meta-analysis. (Full text)

Long-term macrolide treatment for the prevention of acute exacerbations in COPD: a systematic review and meta-analysis. Acute exacerbation of COPD (AECOPD) is associated with an increased hospitalization and mortality. Azithromycin and erythromycin are the recommended drugs to reduce the risk of exacerbations. However, the most suitable duration of therapy and drug-related adverse events are still a matter of debate. The aim of this meta-analysis was to assess the current evidence regarding (...) the efficacy and safety of long-term macrolide treatment for COPD.We comprehensively searched PubMed, Embase, the Cochrane Library, and the Web of Science and performed a systematic review and cumulative meta-analysis of all randomized controlled trials (RCTs) and retrospective studies.Eleven RCTs and one retrospective study including a total of 2,151 cases were carried out. Long-term macrolide treatment significantly reduced the total number of cases with one or more exacerbations (OR=0.40; 95% CI=0.24

2019 International journal of chronic obstructive pulmonary disease PubMed abstract

82. Macrolide antibiotics in the treatment of chronic rhinosinusitis: evidence from a meta-analysis. (Full text)

Macrolide antibiotics in the treatment of chronic rhinosinusitis: evidence from a meta-analysis. The purpose of this study was to systematically assess the subjective and objective outcomes of macrolide therapy for chronic rhinosinusitis (CRS).PubMed, Embase and Cochrane databases were searched for clinical trials detailing the effects of macrolide therapy in patients with CRS and published up to December 2017. Sino-Nasal Outcome Test (SNOT), endoscopic scores and computed tomography scans (CT (...) ) scores were assessed by mean difference (MD) or standardized mean difference (SMD) with 95% confidence interval. Subgroup analyses were performed to evaluate the source of heterogeneity according to study design and geographic locations. I2 metric was used to assess the heterogeneity.Seven randomised clinical trials (RCTs) and four cohort trials meeting pre-determined selection criteria were enrolled in this meta-analysis. Assessment of the findings for SNOT after 12 weeks' macrolide treatment

2019 Journal of thoracic disease PubMed abstract

83. The effects of macrolides in children with reactive airway disease: a systematic review and meta-analysis of randomized controlled trials. (Full text)

The effects of macrolides in children with reactive airway disease: a systematic review and meta-analysis of randomized controlled trials. Childhood reactive airway diseases (RADs) are concerning problems in children's airways and may be preceded by bronchiolitis and may progress to childhood asthma. The severity of the disease is indicated by deterioration in pulmonary functions, increased usage of rescue medications, and recurrent wheezing episodes. Macrolides have both antimicrobial and anti (...) -inflammatory functions and have been used as adjunctive therapy in childhood RADs.We conducted a meta-analysis to evaluate the effect of macrolides in children with RAD. Literature searches were systematically conducted using an electronic database from inception to August 2018. The Cochrane review risk of bias assessment tool was used to assess the quality of each randomized controlled trial.Sixteen randomized controlled trials comprising 1,415 participants were investigated in this meta-analysis

2019 Drug design, development and therapy PubMed abstract

84. [Locally delivered macrolides as an adjunct to non-surgical periodontal treatment of chronic periodontitis: a meta analysis]. (Abstract)

[Locally delivered macrolides as an adjunct to non-surgical periodontal treatment of chronic periodontitis: a meta analysis]. The present meta analysis was designed to determine the effects of macrolides group of antibiotics as local drug delivery agents to scaling and root planing (SRP), compared with SRP alone or plus placebo.Electronic and manual literature searches were conducted to select randomized controlled trials (RCTs) comparing SRP + macrolides versus SRP alone using the following (...) , 95%CI(0.39-1.10), P<0.0001],plaque index(PI)[MD=0.30, 95% CI(0.17-0.43), P<0.00001],modified sulcus bleeding index (mSBI)[MD=0.23, 95%CI(0.15-0.32), P<0.00001]at 3 month and 6 month of PD[MD=1.15, 95%CI(0.41-1.89), P=0.002] were significantly different, the difference of CAL[MD=0.92, 95%CI(0.43-1.40), P=0.0002], PI[MD=0.51, 95%CI(0.07-0.95), P=0.02] and mSBI[MD=0.18, 95%CI(0.07-0.29), P=0.002] was also significant (P<0.05).SRP combined with local macrolides adjuvant treatment for chronic

2019 Shanghai kou qiang yi xue = Shanghai journal of stomatology

85. Impact of Macrolide Antibiotics on Hospital Readmissions and other Clinically Important Outcomes in Critically Ill Patients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Propensity Score-Matched Cohort Study. (Full text)

Impact of Macrolide Antibiotics on Hospital Readmissions and other Clinically Important Outcomes in Critically Ill Patients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Propensity Score-Matched Cohort Study. To assess whether a macrolide-based antibiotic treatment strategy reduces in-hospital mortality, decreases hospital readmissions, or improves other clinically important outcomes compared with a non-macrolide antibiotic treatment strategy in critically ill patients (...) with acute exacerbations of chronic obstructive pulmonary disease (AECOPD).Propensity score-matched pharmacoepidemiologic cohort study.Premier's Perspective Hospital Database.A total of 28,700 adults aged 40 years or older who were admitted to one of 566 United States intensive care units and had the primary diagnosis of AECOPD between January 2010 and December 2014, and received antibiotic treatment within 2 days of hospital admission were included. Patients were divided into macrolide (11,602 patients

2019 Pharmacotherapy PubMed abstract

86. Long-term low rate of macrolide resistant <i>Mycoplasma pneumoniae</i> strains in Germany. (Full text)

Long-term low rate of macrolide resistant Mycoplasma pneumoniae strains in Germany. Mycoplasma pneumoniae is a frequent cause of infections of the lower and upper respiratory tract of humans.….Copyright © 2019 American Society for Microbiology.

2019 Antimicrobial Agents and Chemotherapy PubMed abstract

87. Macrolide combination therapy for hospitalised CAP patients? An individualised approach supported by machine learning. (Abstract)

Macrolide combination therapy for hospitalised CAP patients? An individualised approach supported by machine learning. The role of macrolide/beta-lactam combination therapy in community-acquired pneumonia (CAP) of moderate severity is a matter of debate. Macrolides expand the coverage to atypical pathogens and attenuate pulmonary inflammation, but have been associated with cardiovascular toxicity and drug interactions. We developed a decision tree based on etiological and clinical parameters (...) , which are available ex ante to support a personalised decision pro or con macrolides for the best clinical outcome of the individual patient.We employed machine learning in a cross-validation scheme based on a well balanced selection of 4898 patients after propensity score matching to data available on admission of 6440 hospitalised patients with moderate severity (non-ICU patients) from the observational, prospective, multinational CAPNETZ study. We aimed to improve the primary outcome of 180 days

2019 European Respiratory Journal

88. Meta-analysis of macrolide maintenance therapy for prevention of disease exacerbations in patients with noncystic fibrosis bronchiectasis. (Full text)

Meta-analysis of macrolide maintenance therapy for prevention of disease exacerbations in patients with noncystic fibrosis bronchiectasis. Macrolide maintenance treatment remains controversial for patients with noncystic fibrosis (non-CF) bronchiectasis, we performed a meta-analysis to estimate the benefits and safety of macrolides therapy in adults and children with non-CF bronchiectasis.PubMed, Embase, the Cochrane Library, and Web of Science databases were searched for all the randomized (...) controlled trials of macrolides for treating non-CF bronchiectasis. The primary outcome was improvement of bronchiectasis exacerbations. Secondary outcomes included adverse events and macrolide resistance.A total of 10 studies involving 602 patients were included in the analysis. Pooled results showed that macrolide therapy significantly reduced the number of patients who suffered from exacerbations (RR = 1.56, 95% CI = 1.14-2.14, P = .006, I = 72%), number of patients who experienced at least 3

2019 Medicine PubMed abstract

89. High Prevalence of Macrolide-Resistant Bordetella pertussis and ptxP1 Genotype, Mainland China, 2014-2016. (Full text)

High Prevalence of Macrolide-Resistant Bordetella pertussis and ptxP1 Genotype, Mainland China, 2014-2016. According to the government of China, reported cases of pertussis have increased remarkably and are still increasing. To determine the genetic relatedness of Bordetella pertussis strains, we compared multilocus variable-number tandem-repeat analysis (MLVA) results for isolates from China with those from Western countries. Among 335 isolates from China, the most common virulence-associated

2019 Emerging Infectious Diseases PubMed abstract

90. When guideline treatment of asthma fails, consider a macrolide antibiotic. (Abstract)

When guideline treatment of asthma fails, consider a macrolide antibiotic. This class of drugs has the potential to benefit patients with persistent, poorly controlled asthma and those with new-onset disease as an adjunct to first-line therapy.

2019 Journal of Family Practice

92. Outbreak of macrolide-resistant mycoplasma pneumoniae in a primary school in Beijing, China in 2018. (Full text)

Outbreak of macrolide-resistant mycoplasma pneumoniae in a primary school in Beijing, China in 2018. On 7th June, 2018, a primary school in Beijing, China notified Shunyi CDC of an outbreak of acute respiratory disease characterized by fever and cough among students and resulting in nine hospitalization cases during the preceding 2 weeks. We started an investigation to identify the etiologic agent, find additional cases, develop and implement control measures.We defined probable cases (...) qPCR) assay, a duplex qPCR assay, and sequencing were performed to determine the pathogen, genotype and macrolide resistance at the gene level, respectively.From May 1st to June 31st, 2018, we identified 55 cases (36 probable and 19 confirmed), of whom 25 (45%) were hospitalized for complications. All cases were students, none of the teachers and other staffs in the school were with similar symptoms. The attack rate (AR) was 3.9% (55/1398) for all students. The cases were mainly male (58

2019 BMC Infectious Diseases PubMed abstract

93. Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia (Full text)

Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia International guidelines including those in the UK, Japan, Australia and South Africa recommend the avoidance of macrolides in patients with low-severity community-acquired pneumonia (CAP). We hypothesised that severity scores are poor predictors of atypical pneumonia and response to macrolide therapy, and thus, inadequate tools for guiding antibiotic prescriptions.Secondary analysis of four (...) independent prospective CAP datasets was conducted. The predictive values of the CURB-65 and pneumonia severity index (PSI) for clinically important groups of causative pathogens were evaluated. The effect of macrolide use according to risk class was assessed by multivariable analysis. Patients (3297) were evaluated, and the predictive values of CURB-65 and PSI for atypical pathogens were poor (AUC values of 0.37 and 0.42, respectively). No significant differences were noted among the effects of macrolide

2017 EvidenceUpdates PubMed abstract

94. Cardiac events after macrolides or fluoroquinolones in patients hospitalized for community-acquired pneumonia: post-hoc analysis of a cluster-randomized trial. (Full text)

Cardiac events after macrolides or fluoroquinolones in patients hospitalized for community-acquired pneumonia: post-hoc analysis of a cluster-randomized trial. Guidelines recommend macrolides and fluoroquinolones in patients hospitalized with community-acquired pneumonia (CAP), but their use has been associated with cardiac events. We quantified associations between macrolide and fluoroquinolone use and cardiac events in patients hospitalized with CAP in non-ICU wards.This was a post-hoc (...) analysis of a cluster-randomized trial as a cohort study; including patients with a working diagnosis of CAP admitted to non-ICU wards without a cardiac event on admission. We calculated cause-specific hazard ratio's (HR's) for effects of time-dependent macrolide and fluoroquinolone exposure as compared to beta-lactam monotherapy on cardiac events, defined as new or worsening heart failure, arrhythmia, or myocardial ischemia during hospitalization.Cardiac events occurred in 146 (6.9%) of 2107 patients

2019 BMC Infectious Diseases Controlled trial quality: uncertain PubMed abstract

95. Macrolide therapy for chronic rhinosinusitis: a meta-analysis

Macrolide therapy for chronic rhinosinusitis: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2013 DARE.

96. Macrolide Antibiotics and Survival in Patients with Acute Lung Injury

Macrolide Antibiotics and Survival in Patients with Acute Lung Injury PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2012 PedsCCM Evidence-Based Journal Club

97. Anti-inflammatory effects of adjunctive macrolide treatment in adults hospitalized with influenza: A randomized controlled trial. (Abstract)

Anti-inflammatory effects of adjunctive macrolide treatment in adults hospitalized with influenza: A randomized controlled trial. - Macrolides can ameliorate inflammation in respiratory diseases, providing clinical benefits. Data in influenza is lacking.- A randomized, open-label, multicenter trial among adults hospitalized for laboratory-confirmed influenza was conducted. Study treatments of oseltamivir and azithromycin (500 mg/day), or oseltamivir alone, both for 5 days, were allocated at 1:1 (...) unaffected. Additional ex vivo studies confirmed reduced induction of IL-6 (P = 0.017) and CXCL8/IL-8 (P = 0.005) with azithromycin.- We found significant anti-inflammatory effects with adjunctive macrolide treatment in adults with severe influenza infections. Virus control was unimpaired. Clinical benefits of a macrolide-containing regimen deserve further study. [ClinicalTrials.gov NCT01779570].Copyright © 2017 Elsevier B.V. All rights reserved.

2018 Antiviral research Controlled trial quality: predicted high

98. Macrolides for the treatment of COVID-19: a living systematic review protocol

Macrolides for the treatment of COVID-19: a living systematic review protocol Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2020 PROSPERO

99. Effect of Combined β-Lactam / Macrolide Therapy on Mortality According to the Microbial Aetiology and Inflammatory Status of Patients with Community - Acquired Pneumonia. (Full text)

Effect of Combined β-Lactam / Macrolide Therapy on Mortality According to the Microbial Aetiology and Inflammatory Status of Patients with Community - Acquired Pneumonia. Antibiotic combinations that include macrolides have shown lower mortality rates than β-lactams in monotherapy or combined with fluoroquinolones in patients with community-acquired pneumonia (CAP). However, this effect has not been studied according to the levels of C-reactive protein in CAP with identified microbial cause (...) . In patients with CAP and known microbial cause we aimed to evaluate 30-day mortality of a β-lactam plus macrolide (BL + M) compared with a fluoroquinolone alone or with a β-lactam (FQ ± BL).We analyzed a prospective observational cohort of patients with CAP admitted to the Hospital Clinic of Barcelona between 1996 and 2016. We included only patients with known microbial cause.Of 1,715 patients (29%) with known etiology, a total of 932 patients (54%) received BL + M. Despite lower crude mortality in the BL

2018 Chest PubMed abstract

100. Molecular typing of Treponema pallidum isolates from Buenos Aires, Argentina: Frequent Nichols-like isolates and low levels of macrolide resistance. (Full text)

Molecular typing of Treponema pallidum isolates from Buenos Aires, Argentina: Frequent Nichols-like isolates and low levels of macrolide resistance. A total of 54 clinical samples, including genital lesion swabs, whole blood and cerebrospinal fluid from patients diagnosed with syphilis were collected in 2006 and in 2013 in Buenos Aires, Argentina. Treponemal DNA was detected in 43 of the analyzed samples (79.6%) and further analyzed using Sequencing-based molecular typing (SBMT) and Enhanced

2017 PLoS ONE PubMed abstract

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>